好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Late onset MS is associated with more severe longitudinal development of central brain atrophy compared to adult onset MS
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-019
To examine whether the rate of brain atrophy in late onset multiple sclerosis (LOMS) is higher compared to the age-matched adult onset MS (AOMS) population. 

LOMS is associated with more aggressive clinical course and progressive forms of the disease, but the effect of age of disease onset on the rate of brain atrophy was not previously investigated.
This was a retrospective, longitudinal, single-center cohort study that included 580 MS patients from a pool of 2,200 patients collected over 10 years. MS patients were classified as having LOMS (n=290), if they were >40 years old at disease onset and AOMS (n=290) if they were ≤40 years old. The mean follow-up was 5.5 years and patients were evaluated with clinical and MRI examinations at both baseline and follow-up. T2-lesion volume (LV), percent brain volume change (PBVC) and percent lateral ventricle volume change (PLVVC) were measured over the follow-up. 

The mean age at baseline was 53 (SD 5.9) years in both LOMS and AOMS patients, while the mean disease duration was 6.9 (SD 5.4) and 17.6 (SD 8.8) years, in the two groups, respectively. The median baseline EDSS was significantly higher in AOMS compared to LOMS patients (p<0.001). At baseline, AOMS patients had significantly higher T2-LV (p=0.003) and LVV (p=0.034), and lower whole brain volume (p=0.033). Over the follow-up, LOMS patients showed significantly higher annualized PLVVC compared to AOMS patients (4.1% vs. 1.6%, p<0.001), while there were no significant differences for PBVC and absolute change in T2-LV between the groups. No significant differences in disability progression were observed between the two groups over the follow-up.
LOMS is associated with more severe longitudinal development of central brain atrophy compared to AOMS.
Authors/Disclosures
Dora Dujmic
PRESENTER 		No disclosure on file
Dejan Jakimovski, MD, PhD (Buffalo Neuroimaging Analysis Center, University at Buffalo) Dr. Jakimovski has nothing to disclose.
Jesper Hagemeier No disclosure on file
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo) Prof. Bergsland has nothing to disclose.
No disclosure on file
David Hojnacki, MD, FAAN (University At Buffalo, Jacobs Neurological Institute) Dr. Hojnacki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hojnacki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Hojnacki has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Channa Kolb, MD No disclosure on file
Alexis A. Lizarraga, MD (University At Rochester) Dr. Lizarraga has nothing to disclose.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo) Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.